title: Mono and dual therapy for Helicobacter pylori associated gastritis.
abstract: Sixty patients with Helicobacter Pylori positive non ulcer dyspepsia were randomly allocated to one of the following treatment groups: Group I--norfloxacin 400 mg bid for 10 days, Group II--amoxycillin 500 mg bid plus tinidazole 500 mg bid for 15 days, Group III--colloidal bismuth subcitrate (CBS) 240 mg bid for 4 weeks. H pylori elimination was achieved in 14%, 81%, and 62% in Groups I, II and III respectively. Eradication of H pylori was not observed in Groups I and II, but was achieved in 25% of patients in Group III. Antral gastritis improved in 69% in Group II and 50% in Group III. We conclude that norfloxacin is not effective in H pylori infection. A combination of amoxycillin and tinidazole is highly effective in H pylori elimination with improvement in associated gastritis, but H pylori eradication is not observed with this therapy. CBS is also effective in H pylori elimination though H pylori eradication is achieved in only 25%.
authors.affiliation: Department of Gastroenterology, BYL Nair Hospital, Bombay.
authors.forename: H H
authors.initials: HH
authors.lastname: Gill
authors.forename: H G
authors.initials: HG
authors.lastname: Desai
authors.forename: P R
authors.initials: PR
authors.lastname: Mehta
authors.forename: S
authors.initials: S
authors.lastname: Ranganathan
authors.forename: R H
authors.initials: RH
authors.lastname: Kalro
authors.forename: P K
authors.initials: PK
authors.lastname: Murti
authors.forename: S R
authors.initials: SR
authors.lastname: Prabhu
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D009643:Norfloxacin / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D014011:Tinidazole / Q000627:therapeutic use
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D014011:Tinidazole; D000658:Amoxicillin; C002791:bismuth tripotassium dicitrate; D009643:Norfloxacin